VolitionRX's Nu.Q platform to be touted at major veterinary conference in Houston

VolitionRx Limited’s (NYSEAMERICAN:VNRX) technology to detect cancer in dogs will get a boost this weekend at a major veterinary conference in Houston, Texas.

The Isnes, Belgium-based life sciences company is developing blood-based cancer tests to accurately diagnose a range of cancers in humans. As cancer cells multiply, they are modified in a way that distinguishes them from healthy cells and the traits of the malignant disease appear on the nucleosomes, which are analyzed by Volition’s Nu.Q’s platform.

Recently, Volition has extended its flagship Nu.Q platform into veterinary medicine after discovering that nucleosomes in the blood can also be detected in dogs. The company calls its veterinary platform Nu.Q Vet.

READ: VolitionRx forms new Texas veterinary subsidiary, taps animal health expert Nathan Dewsbury to head it

In a statement Friday, the company said Dr Heather Wilson-Robles, associate professor of oncology at Texas A&M College of Veterinary Medicine & Biomedical Sciences, will present and discuss Volition’s Nu.Q’s technology at the Veterinary Cancer Society Annual Conference. 

The conference is one of the largest veterinary oncology meetings in the world with presentations from keynote speakers, basic science and clinical science abstracts and poster sessions, in addition to technician workshops.

Wilson-Robles’ presentation is entitled “Detection of nucleosomes in the blood of canines with cancer and inflammation” will take place on October 19.

“I am delighted to have the opportunity to introduce the potential use of the Nu.Q technology to the veterinary oncology community at this prestigious event. It is exciting to share some of the encouraging early work we have done together with Volition,” she said.

“This pre-analytical work was important to allow us to plan the product development program for Nu.Q Vet. I believe the early identification of cancer has the potential to significantly impact veterinary oncology as we know it and thereby look forward to developing Nu.Q Vet further.”

READ: VolitionRx hits milestone in Nu.Q Capture blood-based cancer-detection technology

Nathan Dewsbury, CEO of Texas-based Volition Veterinary Diagnostics Development LLC, a company subsidiary, will also be at the meeting.

“There are currently no accurate, simple, affordable cancer screening tests available in veterinary medicine and yet 25% of dogs will develop cancer at some stage in their lives,” he said. “At Volition Veterinary we believe that early diagnosis is the key and are working hard to develop Nu.Q Vet products which can simply and affordably help diagnose cancer and a range of other diseases through a routine blood draw.”

The company’s stock recently traded up 2.2% to $5.55 a share in New York. 

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Story by ProactiveInvestors